PT - JOURNAL ARTICLE AU - Oyungerel Byambasuren AU - Claudia C Dobler AU - Katy Bell AU - Diana Patricia Rojas AU - Justin Clark AU - Mary-Louise McLaws AU - Paul Glasziou TI - Estimating the seroprevalence of SARS-CoV-2 infections: systematic review AID - 10.1101/2020.07.13.20153163 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.13.20153163 4099 - http://medrxiv.org/content/early/2020/07/15/2020.07.13.20153163.short 4100 - http://medrxiv.org/content/early/2020/07/15/2020.07.13.20153163.full AB - Background Accurate seroprevalence estimates of SARS-CoV-2 in different populations could help gauge the true magnitude and spread of the infection seroprevalence. Reported estimates have varied greatly, but many have derived from biased samples, and inadequate testing methods.Objective To estimate the range of valid seroprevalence rates of SARS-CoV-2 in different populations, and compare these seroprevalence estimates with the cumulative cases seen in the same population.Methods We searched PubMed, Embase, the Cochrane COVID-19 trials, and Europe-PMC for published studies and pre-prints from January 2020 to 25 May 2020 that reported anti-SARS-CoV-2 IgG, IgM and/or IgA antibodies for serosurveys of either the general community or of defined sub-populations, such healthcare workers and other organizations.Results Of the 837 studies identified, 49 were assessed and 14 were includable. Included studies represented 10 countries and 100,557 subjects: 9 from randomly selected populations, 2 from healthcare workers, 2 from industry populations, and 1of parturient women. The seroprevalence proportions in 10 studies ranged between 1%-10%, and 2 studies’ estimates under 1%, and 2 over 10% - from the notably hard-hit regions of Gangelt in Germany and from Northwest Iran. The two studies in healthcare workers, in Italy and Spain, had seroprevalence rates at higher range of estimates, with the Barcelona hospitals having a higher rate than the Spanish national survey. For only one study was the seroprevalence estimate higher than the cumulative incidence, though these were proximate for several studies. In five studies, the seroprevalence was similar to the cumulative case numbers in the same population. For seropositive cases not previously detected as COVID-19 cases, the majority had prior COVID-like symptoms.Conclusion The seroprevalence of SARS-CoV-2 mostly less than 10% with the level of infection lower in the general community, suggesting levels well below “herd immunity”. The similarity of seroprevalence and reported cases is several studies, and high symptom rates in seropositive cases suggest that gaps between seroprevalence rates and reported cases are likely due to undertesting of symptomatic people.Funding OB is supported by NHMRC Grant APP1106452. PG is supported by NHMRC Australian Fellowship grant 1080042. CCD is supported by NHMRC Fellowship grant 1123733. KB was supported by NHMRC Investigator grant 1174523. There was no funding source for this study.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form. Prof Mary-Louise McLaws is a member of World Health Organization (WHO) Health Emergencies Program Experts Advisory Panel for Infection Prevention and Control (IPC) Preparedness, Readiness and Response to COVID-19 and WHO IPC Guidance Development Group for COVID-19.Funding StatementThere was no funding source for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:System review of published literature is exempt from IRB.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors declare that data supporting the findings of this study are available within the paper and its supplementary files.